Kidney stone disease frequently presents with acute, severe pain — stone colic — requiring prompt, effective analgesia. Selecting the appropriate first-line agent depends on the patient's individual profile, particularly their cardiovascular risk.
Evidence-based guidance designates a specific class of analgesics — chosen on the basis of cardiovascular risk factors and side-effect profile — as the first drug of choice for acute stone colic, with an additional targeted option considered for stones expected to pass spontaneously. The complete agent selection criteria, sequencing, and management algorithm are available in the full protocol.